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Mutations in RAB39B Cause X-Linked
Intellectual Disability and Early-Onset Parkinson
Disease with a-Synuclein Pathology
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Advances in understanding the etiology of Parkinson disease have been driven by the identification of causative mutations in families.
Genetic analysis of an Australian family with three males displaying clinical features of early-onset parkinsonism and intellectual
disability identified a ~45 kb deletion resulting in the complete loss of RAB39B. We subsequently identified a missense mutation
(c.503C>A [p.Thr168Lys]) in RAB39B in an unrelated Wisconsin kindred affected by a similar clinical phenotype. In silico and
in vitro studies demonstrated that the mutation destabilized the protein, consistent with loss of function. In vitro small-hairpin-
RNA-mediated knockdown of Rab39b resulted in a reduction in the density of a-synuclein immunoreactive puncta in dendritic processes
of cultured neurons. In addition, in multiple cell models, we demonstrated that knockdown of Rab39b was associated with reduced
steady-state levels of a-synuclein. Post mortem studies demonstrated that loss of RAB39B resulted in pathologically confirmed Parkinson
disease. There was extensive dopaminergic neuron loss in the substantia nigra and widespread classic Lewy body pathology. Additional
pathological features included cortical Lewy bodies, brain iron accumulation, tau immunoreactivity, and axonal spheroids. Overall, we
have shown that loss-of-function mutations in RAB39B cause intellectual disability and pathologically confirmed early-onset Parkinson
disease. The loss of RAB39B results in dysregulation of a-synuclein homeostasis and a spectrum of neuropathological features that impli-
cate RAB39B in the pathogenesis of Parkinson disease and potentially other neurodegenerative disorders.Parkinsonism is a neurological syndrome characterized by
tremor, rigidity, balance problems, and a slowing of move-
ment. The most common cause of parkinsonism is Parkin-
son disease (PD [MIM 168600]), which accounts for up to
70%of this syndrome. PD is a commonprogressiveneurode-
generative disorder with motor symptoms due to the death
of dopamine-generating cells, predominantly in the sub-
stantia nigra (SN). The pathological hallmark of PD is accu-
mulation of a-synuclein in Lewy bodies and Lewy neurites,
although additional pathology (such as neurofibrillary tan-
gles [NFTs]) can be observed.1 Recent genetic studies have
driven advances in understanding the molecular pathogen-1Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research
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The Americanesis of PD, and preclinical discovery projects have inves-
tigated compounds that target the identified proteins as
a precursor to etiology-based therapeutics. To date, 18 PD-
associated loci have been reported, and variants in 13mono-
genic or susceptibility genes have been identified.2 Com-
mon pathogenic mechanisms associated with these genes
include protein turnover, mitochondrial function, and
oxidative-stress pathways. However, approximately 90% of
individuals with PD do not have a defined genetic etiology.
Variants in known genes account for ~10% of the variation
in PD liability, suggesting that variants in additional genes
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Figure 1. Identification of Mutations in
RAB39B
(A and B) Simplified pedigree structure of
the Australian (A) and Wisconsin (B) kin-
dreds. Asterisks indicate DNA samples
analyzed.
(C) Immunoblot analysis (12162-1-AP,
Proteintech; 1:1,000) of RAB39B in BE(2)-
M17 neuroblastoma cells grown in the
absence or presence of 10 mM MG-132.
Abbreviations are as follows: Un, untrans-
fected; WT, wild-type; and p.T168K,
RAB39B p.Thr168Lys. b-actin was used
for confirming equivalent protein loading
(A5441, Sigma-Aldrich; 1:5,000).
(D) Representative images ofmouse hippo-
campal neurons transduced with lentiviral
vectors encoding GFP and either scramble
(shScr) or shRab39b sequences. Images
were captured, and Z-space slices (0.3–
0.4 mm) were deconvolved and flattened
by maximum projection. ImageJ analysis
software (the ‘‘Gran filter’’ plug-in set the
size from 1 to infinity) was used tomeasure
a-synuclein density relative to the area of
infected dendrites. Quantification showed
a significant reduction (0.525 0.03 versus
0.765 0.03, mean5 SEM, p% 0.0005) in
the density of a-synuclein immunoreac-
tive puncta in neurons downregulated for
Rab39b. The experiment was performed
in triplicate (n ¼ 42 neurons scored). The
scale bar represents 20 mm.We identified an Australian kindred with three brothers
who presented in childhood with nonprogressive intellec-
tual disability (ID), which included delayed developmental
milestones, cognitive impairment, and macrocephaly
(Figure 1; Table S1, available online). Subsequently, early-
onset parkinsonism (onset prior to 45 years of age) was
also apparent, although the clinical progression and pre-
sentation varied. The proband developed tremor in late
childhood, but the symptoms did not progress to frank
parkinsonism. In contrast, his male siblings developed
tremor from their late 30s and were diagnosed with
L-DOPA-responsive akinetic-rigid PD by their mid-40s. A
complete description of the phenotype is presented in
Table S1. We collected samples from the Australian family
after receiving institutional ethics approval from Royal
Childrens Hospital (Melbourne) and written informed
consent from participants. Genomic DNA was isolated
from whole blood, and primary fibroblast cultures were
generated according to standard protocols. SNP array and
linkage analysis using a recessive homozygous model did
not demonstrate linkage to the autosomes but did identify
two ~10.6 Mb haplotypes shared by the affected brothers
at Xp22.2 and Xq27.3–qter (chrX: 3,624,034–14,291,092
and chrX: 145,644,895–tel, respectively; GRCh38/hg38,730 The American Journal of Human Genetics 95, 729–735, December 4, 2014UCSC Genome Browser; Table S2).
Copy-number variation and subse-
quent PCR analysis identified a ~45
kb deletion within the Xq haplotype(ClinVar accession number SCV00019029). The deletion
segregated with the disease and resulted in the complete
deletion of RAB39B (RAB39B, member RAS oncogene fam-
ily [MIM 300774]) and the last three coding exons of
CLIC2 (chloride intracellular channel 2 [MIM 300138]).
To assess RAB39B expression, we extracted total RNA
from fibroblasts by using the SV Total RNA Isolation Sys-
tem (Promega) and synthesized cDNA with the Transcrip-
tor First Strand cDNA Synthesis Kit (Roche). Consistent
with the genomic data, the RAB39B and CLIC2 transcripts
were not detected by RT-PCR analysis of fibroblast cells
derived from affected individuals (Figure S1).
The phenotype of the Australian kindred is similar to the
basal ganglia disorder (Waisman syndrome [MIM 311510])
reported for aWisconsin kindred5 (Figure 1; Table S1).Mem-
bers of the defining family included 13 affected males who
presented with variable degrees of ID and early-onset
parkinsonism.Multipoint linkage analysis of theWisconsin
family previously localized the disease-causing mutation to
Xq27.3–qter with a maximum multipoint LOD of 6.75 at
the genetic marker F8C (chrX:154,929,351–154,929,630;
GRCh38/hg38). The minimal Xq linkage region in the
Australian kindred is within the Xq27.3–qter interval and
therefore defines the shared critical linkage interval.6
Figure 2. In Silico Modeling of the RAB39B Structure Predicts
that p.Thr168Lys Is Destabilizing
(A) We generated a molecular model of the RAB39B structure
(blue) by superimposing the structures of several known RAB pro-
teins (gray) available in the Protein Data Bank (YTP1 [PDB 2BCG],
RAB1A [PDB 3TKL], RAB11B [PDB 2F9L], RAB18 [PDB 1X3S],
RAB23 [PDB 1Z2A], and RAB30 [PDB 2EW1]). GTP (green sticks)
and Mg2þ (magenta sphere) are from the structure of RAB5A after
superposition.
(B) We then used the predicted RAB39B structure (blue) to model
the position of the native (Thr168, red) and altered (Lys168, yel-
low) amino acid. In the native form, Thr168 is predicted to
interact with Leu60 within the interswitch region of RAB39B.
The internal placement of the large positively charged residue in
the p.Thr168Lys protein is predicted to destabilize the protein.
The quality of the model was tested with PROCHECK,12 ANO-
LEA,13 and Verify3D.14Genomic DNA from individuals of the Wisconsin kindred
was kindly provided by Professor Ronald Gregg. Ethics
approval was provided by the institutional review board
(IRB) at the University of Wisconsin, and informed consent
was obtained. Direct sequencing of RAB39B identified a
missense mutation (c.503C>A [p.Thr168Lys]; RefSeq acces-
sion number NM_171998.2, ClinVar SCV000190018) that
segregated with disease (Figure S2) and was not detected
in 200 unrelated control individuals or public databases
(dbSNP137 and ESP6500). The threonine residue is con-
served in evolution (Figure S3), and the mutation is pre-
dicted to be damaging by PolyPhen-2 and SIFT. In contrast,
no sequence variants were observed by direct sequencing of
CLIC2 in the Wisconsin kindred.
The absence of mutations in CLIC2 in the Wisconsin
kindred suggests that disruption of RAB39B is the cause
of the shared phenotype in both families. It is possible
that deletion of CLIC2 in the Australian kindred might
act as a disease modifier, although the phenotypic features
(seizures and cardiac anomalies) associated with amissenseThe Americanmutation in CLIC2 were not observed.7 X chromosome
exome sequencing of affected males from both kindreds
confirmed the deleterious RAB39B changes and did not
identify any other candidate variants within the linkage re-
gions (Table S3).
In silico modeling of RAB39B was performed with the
structure prediction programs MODELER8 and HHpred,9
and protein structures were visualized and superimposed
with PyMOL. This analysis suggested that Thr168 is buried
within the wild-type protein and interacts with Leu60 in
the interswitch region, which undergoes conformational
changes upon GTP-GDP exchange10,11 (Figure 2). The mu-
tation introduces a large, positively charged lysine residue
that is predicted by multiple algorithms, including ERIS15
and PoPMuSiC,16 to destabilize the protein. We could not
directly test this because endogenous RAB39B was not
detectable in fibroblast cells; therefore, we generated stable
BE(2)-M17 neuroblastoma lines overexpressing wild-type
RAB39B and altered (p.Thr168 Lys) RAB39B. The complete
RAB39B open reading frame was amplified from human
brain cDNA and cloned into the mammalian expression
vector pcDNA3.1 (Invitrogen). We used site-directed muta-
genesis (QuickChangeII) to generate the p.Thr168Lys
altered RAB39B construct and Sanger sequenced all clones
to verify that no additional variants were present. RT-PCR
analysis confirmed similar expression of the wild-type and
altered constructs (data not shown). In contrast, immuno-
blot analysis revealed high steady-state levels of exogenous
wild-type RAB39B but very low levels of exogenous altered
RAB39B. Immunoblot and immunofluorescence analysis of
the cells after treatment with the proteasome inhibitorMG-
132 confirmed that the reduced steady-state level of altered
RAB39B was due to rapid turnover of the protein by the
ubiquitin proteasome system (Figure 1; Figure S4). These re-
sults confirm the in silico modeling suggesting that the
altered protein is destabilized and collectively demonstrate
that loss of function of RAB39B causes ID and parkin-
sonism. Previous studies have associated RAB39Bmutations
with ID17–19 (pedigrees D-23 and MRX72; Table S1). The
absence of parkinsonism in these additional families could
be due to the individuals’ age at reporting, given that our
data suggest that parkinsonism is likely to manifest after
the second decade, albeit with some variability in both
onset and clinical severity (Table S1). However, the lack of
clinical data and inability to re-examine affected individ-
uals mean that it is difficult to determine whether the
phenotype associated with loss of RAB39B function repre-
sents an age-dependent progression of ID and parkin-
sonism or a spectrum of heterogeneous phenotypes extend-
ing from ID to ID with parkinsonism (see below).
Rab GTPases belong to the Ras superfamily of small
GTPases and act as essential regulators of vesicular traf-
ficking. They dynamically localize to distinct intracellular
membranes and regulate vesicular transport by recruiting
effector proteins.20 The precise localization and function
of RAB39B is unknown, but the protein is thought to
play a role in synapse formation and maintenance.17,18,21Journal of Human Genetics 95, 729–735, December 4, 2014 731
Figure 3. Neuropathology Associated with Loss of RAB39B
CNS postmortem tissue from II:1 was collected at autopsy, and microscopic examination was performed on H&E-stained sections. To
detect PD-associated proteins, we applied immunohistochemistry to 5 mm formalin-fixed paraffin-embedded sections as previously
described.25 Primary antibodies utilized were anti-a-synuclein (97/8; 1:1,000)23 and anti-tau (A0024, Dako; 1:500). CNS nonhaem
iron (Fe2þ and Fe3þ) was detected with a previously described Perl’s methodology.26 The scale bar represents 50 mm (A) or 20 mm (B–F).
(A–E) SN sections show (A) neuronal loss and pigment incontinence (H&E), (B) intraneuronal Lewy bodies (H&E), (C) a-synuclein-reac-
tive Lewy bodies and neurites, (D) tau-immunoreactive intraneuronal NFTs, and (E) extracellular iron deposition (Perl’s stain).
(F) Neocortical Lewy bodies were identified by H&E staining.In support of this, we observed colocalization of endoge-
nous RAB39B with markers of the vesicular-transport
pathway, particularly the early endosome in mouse and
human neuroblastoma cells (Figure S5). Given the post-
mortem results (below) and the association between a-syn-
uclein and vesicular-trafficking pathways,22 we tested the
effect of downregulation of RAB39B on a-synuclein locali-
zation. Mouse hippocampal neurons were prepared and
transduced with lentivirus expressing validated Rab39b
small hairpin RNA (shRNA) as previously described.17
Fourteen days after transduction, we observed that the
density of a-synuclein immunoreactive puncta in the den-
dritic processes was 30% lower than in the cells transduced
with the scramble control shRNA (p % 0.0005; Figure 1;
Figure S6). Immunoblot analysis confirmed ~40% reduc-
tion of RAB39B but also demonstrated that a-synuclein
levels (detected with the anti-a-synuclein antibody 97/
8,23 1:1,000) were reduced by ~50% (p% 0.05; Figure S6).
Similarly, in P19 mouse neuroblastoma cells, immunoblot
analysis demonstrated that shRNA-mediated knockdown
of Rab39b resulted in ~50% reduction in a-synuclein
steady-state levels (p % 0.005; Figure S6). Although the
mechanism remains to be fully defined, these results sug-
gest that downregulation of RAB39B results in dysregula-
tion of a-synuclein homeostasis. We sequenced RAB39B
in a cohort of 187 individuals with early-onset PD; they
had been previously sequenced and shown not to have
mutations in known PD-associated genes, including
SNCA (MIM 163890), PARK2 (MIM 602544), DJ1 (MIM
602533), PINK1 (MIM 608309), and LRRK2 (MIM732 The American Journal of Human Genetics 95, 729–735, Decemb609007).24 This analysis did not identify any additional
variants, suggesting that mutations in RAB39B are not a
common cause of early-onset PD.
To determine whether the parkinsonism observed in the
affected individuals resulted from PD, we investigated the
neuropathology associated with the loss of RAB39B. Indi-
vidual II:1 died at age 48 years from positional asphyxia.
Postmortem neuropathological studies on the brain of
II:1 were consistent with PD. The macroscopic findings
were unremarkable, and serial coronal sections showed
normal cortex, white matter, and ventricles with normal-
appearing basal ganglia and thalamus. Cross section of
the brain stem showed pallor of the SN and locus coeru-
leus. SN sections stained with haematoxylin and eosin
(H&E) revealed hallmark neuropathological PD features,
including loss of pigmented neurons and Lewy bodies in
surviving neurons (Figure 3). Immunoreactive staining re-
vealed the presence of a-synuclein-positive Lewy bodies
and Lewy neurites in>10% of the surviving neurons. Addi-
tional neuropathological features included an abundance
of cortical Lewy bodies, which are a pathological feature
characteristic of dementia with Lewy bodies (DLB [MIM
127750]; reviewed in27,28). Tau-immunoreactive NFTs
were also observed in a small proportion of the surviving
pigmented SN neurons (Figure 3). Tau pathology has previ-
ously been observed in familial and idiopathic PD, and the
tau-encoding gene (microtubule-associated protein tau
[MAPT (MIM 157140)]) exists within a PD susceptibility
locus. Tau plays a role in iron homeostasis,29–31 and Perl
staining revealing a modest accumulation of iron in theer 4, 2014
SN (Figure 3) was consistent with the slight reduction in T2
signal intensity observed in individual II:1 (Table S1). In
addition, analysis of the basal ganglia identified rare axonal
spheroids in the white-matter tracts (data not shown),
similar to the Wallerian-like degeneration observed in
neurodegenerative diseases with impaired axonal trans-
port.32 The additional pathological and clinical features
share similarities with other neurodegenerative disorders,
the most similar of which was neurodegeneration with
brain iron accumulation (NBIA [MIM 234200]). Notably,
in rare cases, NBIA can manifest with developmental delay
and subsequent early-onset parkinsonism.33 AlthoughMRI
of II:3 was normal and II:1 did not show symptoms typical
of NBIA,34 genomic DNA from individuals with NBIA was
analyzed. Ethics approval was provided by the IRB at Ore-
gon Health & Science University, and informed consent
was obtained. Sequence analysis of RAB39B in a cohort of
48 male individuals with NBIA of unknown etiology did
not identify any variants.
In conclusion, genetic studies have demonstrated that
loss of RAB39B causes pathologically defined PD, and func-
tional studies have provided additional evidence for patho-
genicity. Our results link the loss of a single gene involved
in neuronal organization and synaptic function to the early
manifestation of both ID and neurodegeneration and sug-
gest that the loss of RAB39B dysregulates a-synuclein. For
the two families we ascertained and clinically characterized,
there appears to be a canonical age-dependent progression,
namely ID first and then a slowly progressive basal ganglia
disorder that advances after puberty. This was observed or
reported in all 16 affected males in the Australian and Wis-
consin families. However, given the lack of clinical data for
the other two families previously described to be affected by
RAB39B mutations,17 it is unclear whether this age-depen-
dent phenotype predominates or whether heterogeneous
phenotypes extending from ID to ID with parkinsonism
are associated with loss of RAB39B function. This issue
will be resolved by future studies of additional individuals
with mutations in RAB39B.
The proposed role of RAB39B in vesicular trafficking
identifies a potential disease mechanism that is distinct
from pathways associated with genes in which mutations
are currently known to cause familial early-onset PD. Previ-
ous in vitro studies have demonstrated that a-synuclein-
mediated deficits in vesicular trafficking can be amelio-
rated by the overexpression of several RAB proteins35,36
but have not shown that loss of a specific RAB can cause
PD. Current studies are further investigating how loss of
RAB39B might cause the observed in vitro deficits in local-
ization and reduced steady-state levels of a-synuclein but
in vivo accumulation of significant a-synuclein pathology
at end-stage disease. It is possible that in simple cell models
with efficient protein-metabolism pathways, the ‘‘mislo-
calized’’ a-synuclein is rapidly turned over and thus leads
to reduced steady-state levels. However, protein-turnover
pathways are compromised in individuals with PD;37
therefore, mislocalized a-synuclein might not be turnedThe Americanover efficiently, and as the disease progresses, the protein
could accumulate and be incorporated into the protein ag-
gregates that define PD.
The broader pathology of iron accumulation, NFTs, and
axonal spheroids is similar to that reported for a range of
neurodegenerative conditions. However, the abundance
of both brainstem and cortical Lewy bodies suggests that
RAB39B and/or associated pathways might directly
contribute to the pathogenic mechanisms underlying de-
mentia disorders such as DLB. Further studies, including
the development of animal models, will be important for
understanding the underlying pathogenic mechanism(s)
of RAB39B dysfunction and identifying potential targeted
therapeutic interventions.Supplemental Data
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